JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential thrombocythemia according to JAK2 or CALR mutation status and in relation to those of polycythemia vera. The mutant alle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rumi, Elisa, Pietra, Daniela, Ferretti, Virginia, Klampfl, Thorsten, Harutyunyan, Ashot S., Milosevic, Jelena D., Them, Nicole C. C., Berg, Tiina, Elena, Chiara, Casetti, Ilaria C., Milanesi, Chiara, Sant’Antonio, Emanuela, Bellini, Marta, Fugazza, Elena, Renna, Maria C., Boveri, Emanuela, Astori, Cesare, Pascutto, Cristiana, Kralovics, Robert, Cazzola, Mario
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3945864/
https://ncbi.nlm.nih.gov/pubmed/24366362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-539098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados